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SUMMARY
Vaccines have revolutionized public health, prevent-
ing millions of deaths each year, particularly in
childhood. Yet, there is considerable variability in
the magnitude and persistence of vaccine-induced
immunity. Maintenance of specific antibody is essen-
tial for continuity of vaccine-induced serological pro-
tection. We conducted a genome-wide association
study into the persistence of immunity to three child-
hood vaccines: capsular group C meningococcal
(MenC), Haemophilus influenzae type b, and tetanus
toxoid (TT) vaccines. We detail associations between
variants in a locus containing a family of signal-regu-
latory proteins and the persistence MenC immunity.
We postulate a regulatory role for the lead SNP, with
supporting epigenetic and expression quantitative
trait loci data. Furthermore, we define associations
between SNPs in the human leukocyte antigen
(HLA) locus and the persistence of TT-specific immu-
nity. Moreover, we describe four classical HLA alleles,
HLA DRB1*0301, HLA DQB1*0201, HLA DQB1*0602,
and HLA DRB1*1501, associated with TT-specific
immunity, independent of the lead SNP association.
INTRODUCTION
Vaccination will prevent an estimated 23.3 million deaths this
decade (2011–2020) (Lee et al., 2013). Globally, polysaccha-
ride-encapsulated organisms are the leading cause of bacterial
meningitis and pneumonia in children. Haemophilus influenzae
type b (Hib) and Neisseria meningitidis are estimated to cause
8.13 million and 500,000 serious illnesses worldwide each
year, respectively (Watt et al., 2009; Wilder-Smith and Memish,
2003). Over 150,000 Hib and 50,000meningococcal cases result
in death each year (GBD 2013 Mortality and Causes of Death
Collaborators, 2015). Tetanus is an acute and life-threatening
disease, caused by the bacterium Clostridium tetani. An esti-
mated 61,000 deaths resulted from neonatal tetanus in the
year 2011 alone (World Health Organization, 2017).
Unlike plain polysaccharide vaccines, conjugate vaccines (i.e.,
polysaccharides chemically conjugated to carrier proteins such
as tetanus toxoid [TT]) are T cell-dependent antigens that are
immunogenic from early infancy (Pollard et al., 2009; Black
et al., 1991). In the United Kingdom, introduction of national im-
munization programs with the Hib conjugate vaccine (1992—)
and the capsular group Cmeningococcal (MenC) conjugate vac-
cine (1999—) resulted in the virtual disappearance of invasive
disease caused by these organisms (Miller et al., 2001; Salisbury
et al., 2014). However, persistence of serum antibody to encap-
sulated bacteria such as Hib and MenC is essential for direct
protection against these rapidly invading pathogens (McVernon
et al., 2003; Snape et al., 2006). During a resurgence of Hib dis-
ease in the United Kingdom, Hib was found to be still colonizing
older healthy children, and invasive disease was observed in
some preschool children despite demonstrable immunological
memory, indicating the failure of B cell memory to confer direct
protection or block transmission (McVernon et al., 2003;
Oh et al., 2008).
Unfortunately, following immunization with Hib conjugate and
MenC conjugate vaccines in early infancy, antibody levels
rapidly wane. By 1 year of age, >25% and >50% of children
have antibody levels below the putative threshold of protection
for Hib conjugate and MenC organisms, respectively (Trotter
et al., 2003; Pace et al., 2015). In the United Kingdom, booster
doses of Hib andMenC vaccines were introduced for all children
at 1 year of age in 2003 and 2006, respectively (McVernon et al.,
2003). Yet, the majority of older children were found to lack
protective antibodies levels after the 12-month booster dose
of MenC vaccine, prompting the recent introduction of an
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adolescent dose of MenC (in the form of a quadrivalent Men-
ACWY vaccine) to induce herd immunity and prevent transmis-
sion to younger children (Perrett et al., 2010; Pace et al., 2015;
Public Health England, 2014). The mechanisms underlying the
persistence of antibody are of major interest, because effective-
ness and acceptability of vaccines would be improved if protec-
tion were sustained after infant immunization without the need
for repeated boosting through childhood.
A number of factors have been implicated in determining vac-
cine responses and the persistence of immunity: age, sex,
ethnicity, microbiota, nutritional status, and infectious diseases
(Siegrist and Aspinall, 2009; Klein et al., 2015; Kollmann, 2013;
Savy et al., 2009; Brodin et al., 2015; Nguyen et al., 2016). Impor-
tantly, twin studies have also shown vaccine-induced immunity
to be highly heritable, and recent studies have started to unpick
the genetic components underlying this complex trait (Newport
et al., 2004; O’Connor and Pollard, 2013; Mentzer et al., 2015;
O’Connor et al., 2014; Davila et al., 2010; Png et al., 2011).
The genome-wide association study (GWAS) approach has
already provided considerable insight into the genetic basis of
a number of complex immune-related diseases (Parkes et al.,
2013; Visscher et al., 2017). Here we used a two-stage GWAS
approach to evaluate the genetic determinants of the persis-
tence of immunity to three routine childhood immunizations:
MenC conjugate vaccine, Hib conjugate vaccine, and tetanus
vaccine.
RESULTS
Participants and Study Design
DNAwas available from 3,602 children from nine vaccine studies
conducted in Oxford, United Kingdom, and one vaccine study
conducted in Bilthoven, the Netherlands (Blanchard-Rohner
et al., 2013; de Voer et al., 2010; Khatami et al., 2011, 2014;
Pace et al., 2007; Snape et al., 2006, 2008a, 2008b, 2010; Wad-
dington et al., 2010). Median age at last vaccination was
1,966 days (interquartile range [IQR], 125–3,701.5), and median
time since vaccination was 1,478 days (IQR, 287–1,769). Partic-
ipant demographics are shown in Table S1. The two-stage
GWAS design is illustrated in Figure 1. The discovery cohort
(n = 2,061) was genotyped using the Illumina Omniexpress-
12v1 or Omniexpress-12v1.1 microarray. Genotypes were
further imputed using the 1000 Genomes Phase I integrated
variant set release (March 2012) as the variant reference set
(1000 Genomes Project Consortium et al., 2012). Approximately
6.7 million SNPs were included in quantitative trait associ-
ation analyses of four log10 normalized vaccine-induced immu-
nological measures: MenC-specific immunoglobulin G (IgG)
concentrations, MenC-specific serum bactericidal antibody
(SBA) titers (functional antibody), Hib polyribosylribitol phos-
phate (PRP)-specific IgG concentrations, and TT-specific IgG
concentrations.
The genomic control (lGC) inflation factors for MenC-specific
IgG, MenC-specific SBA, PRP-specific IgG, and TT-specific
IgG were 1.013, 1.010, 1.002, and 1.019, respectively (Figures
S1A–S1D). The percentage of overall variance, in each of the
immunological measures, explained by genetic information
captured on the genotyping microarray (i.e., heritability) varied
from 14% to 81% (Table 1). On the basis of the discovery stage,
we selected 276 SNPs for replication-stage genotyping
(Table S2). Replication SNPs were genotyped using either Se-
quenom or TaqMan assays on both the discovery (n = 2,061)
and replication (n = 1,541) cohorts. A genome-wide significance
threshold of p < 53 108 was set, and two independent loci were
found to surpass this threshold in combined (discovery + replica-
tion) analysis (Tables 2 and 3).
MenC Conjugate Vaccine
Manhattan plots of the results of the discovery stage association
analyses are displayed in Figure 2. Twenty-four SNPs had sug-
gestive statistical associations (p < 1 3 105) with the persis-
tence of MenC-specific IgG concentrations, 13 of which were
within six genes: SENP2, NBEA, LRFN5, MCTP2, GALR1, and
GGT5 (Table S3). Seventy-four SNPs had suggestive association
with the persistence of MenC-specific SBA titers, of which
50 resided within nine genes: ALK, CNTN6, FAM124B,
LINC00265, NPAS3, PDLIM1, PTPRD, SIRPG, and SLC1A3
(Table S3).
A subset of SNPs from the discovery stage were selected for
genotyping in the replication cohort; these were selected to cap-
ture the most credible association signals in a parsimonious
manner (as described in the STAR Methods). A total of 69 and
57 SNPs were selected to capture the association signals of
MenC-specific IgG concentrations and SBA titers, respectively.
Nine and 12 of these SNPs failed Sequenom iPLEX design, leav-
ing 60 and 45 SNPs for MenC-specific IgG and SBA replication
analyses, respectively (Table S2).
A single locus was found to contain SNPs that were signifi-
cantly (p < 5 3 108) associated with the persistence of MenC-
specific SBA titers in combined analysis of discovery and
replication data (Table 2; Table S4). The SNP most significantly
associated with MenC-specific SBA titers was rs6135736 (p =
6.0 3 109, dominant model), which lies within LOC105369219
(gene of unknown function) and <50 kb from the transcription
start site of SIRPG. Themeta-analysis of summary data from dis-
covery and replication cohorts is shown in Table S5. Results of
the combined analysis (i.e., mega-analysis) and meta-analysis
were highly correlated (Pearson’s correlation coefficient > 0.98;
Figures S1E and S1F).
The SNPs associated with the persistence of MenC-specific
SBA titers were within a genomic region containing a family of
signal-regulatory proteins: SIRPA, SIRPB, and SIRPG. Using the
densely genotyped discovery dataset, the association signal ap-
pears to be confined to a region incorporating SIRPG, but sepa-
rated from the other two signal-regulatory proteins (SIRPs) by
recombination hotspots (Figure S2). The HaploReg tool (http://
www.broadinstitute.org/mammals/haploreg) was used to sys-
tematically mine the Roadmap Epigenomics Consortium dataset,
finding several variants to reside within putative promoter and
enhancer regions, in a number of tissues including blood cells,
thymus, and spleen (Romanoski et al., 2015; Ward and Kellis,
2012). Moreover, the lead SNP at this locus (i.e., most statistically
associated with MenC SBA titers), rs6135736, was predicted to
substantially alter the motifs of four TFs: serum response factor
(SRF), zinc-finger protein 410 (ZNF410), retinoic acid receptor
gamma (RARg), and RAR-related orphan receptor alpha (RORa)
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(Figure S1I). Moreover, this SNP is an expression quantitative trait
locus (eQTL) for SIRPG and SIRPB1 (Figures S1J and S1K).
Hib Conjugate Vaccine
A total of 122 SNPs had regression p values suggestive of asso-
ciation (p < 1 3 105) with the persistence of PRP-specific IgG
concentrations (Figure 2C). These SNPs were within five
annotated genes: FOXP1, PDSS2, MLXIPL, CSMD3, and IGL
(immunoglobulin lambda locus). Seventy-five variants were
selected for replication analysis following the SNP pruning algo-
rithm (https://github.com/dan-scholar/LD_pruning). Six of these
SNPs failed Sequenom iPLEX design; none of the remaining
69 SNPs surpassed the level of genome-wide significance in
the combined analysis of discovery and replication cohorts
(Table S4).
TT Vaccine
In the discovery stage, 111 SNPs in eight genes surpassed the
level of suggestive association with TT-specific IgG concentra-
tions: CDH9, MICB, HLA-DQA1, DOCK4, DENND1A, LHPP,
TMEM135, and RBFOX3 (Figure 2D). Furthermore, five SNPs in
an intergenic region of chromosome 10 surpassed the level of
genome-wide significance (p < 5 3 108); the closest gene
(<250 kb) to these associations was TCERG1L. Seventy-seven
SNPs were selected for replication. Twenty-two of these SNPs
failed Sequenom iPLEX design, leaving 55 SNPs for genotyping.
As anticipated, the replication SNPs selected within the human
leukocyte antigen (HLA) locus failed Sequenom iPLEX design;
due to the polymorphic nature of this locus, iPLEX primer design
is problematic. Therefore, conditional linear regression analysis
was used to select five HLA SNPs for genotyping using the
TaqMan SNP genotyping methodology.
None of the Sequenom genotyped SNPs surpassed the level
of genome-wide significance in combined analysis (Table S4).
The lead SNP (rs75727401) in the intergenic region of chromo-
some 10 that reached the genome-wide significance threshold
in the discovery stage was not assessed because it failed
Sequenom quality control (QC). However, this locus was tagged
by rs79697632 (r2 of 0.88 with rs75727401), which was not
found to substantiate the initial GWAS finding. A SNP in HLA
Figure 1. Study Design
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(rs2523650), typed on the TaqMan platform, did surpass the level
of genome-wide significance in the combined analysis and
meta-analysis (Table 3; Table S6). This variant resides within
MICB-DT (gene of uncertain function) and is annotated as an
eQTL for HLA-DRB1 and HLA-DRB5 on the HaploReg database
(http://www.broadinstitute.org/mammals/haploreg).
Classical Human Leukocyte Antigen Alleles
The discovery GWAS dataset was used to impute 168 classical
HLA alleles (Table S7). Four alleles, HLA-DQB1*0201, HLA-
DRB1*0301, HLADQB1*0602, andHLADRB1*1501, were signif-
icantly associated with TT-specific IgG concentrations, after
correction for multiple testing (i.e., by number of HLA alleles
tested; p < 0.05/168) (Table 4). In silico epitope mapping pre-
dicted DRB1*0301 to have the fewest strong and weak binding
affinity to TT epitopes of the panel ofHLA-DRB1 alleles assessed
(Figure S3). Conditional analysis, by including HLA DRB1*0301,
HLA DQB1*0201, HLA DQB1*0602, or HLA DRB1*1501 as cova-
riates in the linear regression model, implied the lead SNP asso-
ciation (rs2523650) was independent of these classical alleles
(Table S8). Results of the classical HLA association analyses
conditioning on HLA DRB1*0301, HLA DQB1*0201, HLA
DQB1*0602, or HLA DRB1*1501 are shown in Table S9.
Pleiotropic Loci Associated with Immunity to Childhood
Immunizations
A total of 301 genes contained SNPs with a regression (additive
model) p < 13 104, with one or more vaccine-induced serolog-
ical measures (Figure 3). Nine of these genes were shared with
more than one vaccine-induced immunological measure (Fig-
ure 3). Two genes, SRSF7 and RP11-115H18.1, shared the
same SNPs between these serological measures and were
therefore correlated and concordant (Table S10).
DISCUSSION
Evoking robust and sustained vaccine-induced immunity from
early life is a crucial component of global health initiatives to
combat the humanitarian burden of infectious disease. Here
we provide a GWAS of persistence of immunity following three
routine childhood vaccines: MenC conjugate vaccine, Hib conju-
gate vaccine, and TT vaccine. We describe two genetic loci
associated (p < 5 3 108) with the persistence of vaccine-
induced immunity following childhood immunization.
First, we present a statistical association between SNPswithin
a genomic region containing a family of signal-regulatory pro-
teins (SIRPs, SIRPA, SIRPB, and SIRPG) and the persistence
of MenC-specific SBA titers. SIRPs are part of the immunoglob-
ulin superfamily, structurally similar to the antigen receptors but
non-rearranging (van den Berg et al., 2004; Barclay and Brown,
2006). SIRP genes are termed ‘‘paired receptors’’ because they
have similar extracellular regions but differing signaling poten-
tials (Barclay and Brown, 2006). SIRPa has an inhibitory cyto-
plasmic motif, SIRPb associates with an activating motif, and
SIRPg has a short cytoplasmic tail that is not believed tomediate
signal transduction (Barclay and Brown, 2006; Nettleship et al.,
2013). Whereas SIRPa and SIRPg bind CD47, the ligand for
SIRPb has yet to be identified (Seiffert et al., 2001; Brooke
et al., 2004). SIRPa is expressed mainly by myeloid cells and
has an important role in innate immune recognition and regula-
tion (Dai et al., 2017). However, SIRPg is expressed by T cells
and a subset of B cells, and engagement of SIRPg on T cells
by CD47 on antigen-presenting cells has been shown to
enhance antigen-specific T cell proliferation (Piccio et al.,
2005; Barclay and Brown, 2006). Upregulation of the SIRPG
gene transcript has been observed in peripheral blood samples
taken 7 days after vaccination with trivalent inactivated influenza
or meningococcal (ACWY) vaccine, supporting a role for this
gene in vaccine responses (Nakaya et al., 2011; O’Connor
et al., 2017).
The SNPs most significantly associated with the persistence
of MenC-specific antibody were intronic and intergenic. It is
possible that low-frequency nonsynonymous coding variant(s)
functionally underpins this association. However, it is nowwidely
understood that regulatory, rather than protein-coding, variants
underlie the majority of association signals arising from GWASs
of complex phenotypes (Maurano et al., 2012). To further explore
the theory of an underlying regulatory variant, we leveraged
epigenetic and transcription factor motif data to assess the can-
didacy of the associated variants. Epigenetic data show the lead
SNP (rs6135736) to be delineated by histone modifications char-
acteristic of an active enhancer, in mitogen-stimulated T helper
cells. Also, this SNP was predicted to severely alter the motifs
of four transcription factors. Furthermore, this SNP is associated
with the expression of two proximal genes (SIRPG and SIRPB1)
in whole blood.
We found that the SIRP locus association was limited to
MenC-specific SBA titers and was not identified in the analysis
of total MenC-specific IgG concentrations. Bactericidal antibody
(measured by SBA) is contingent on antibody subclass and bind-
ing affinity, and thereforemechanistically links this association to
the production of antibody with the functional ability to induce
complement-mediated cytolysis (Michaelsen et al., 1991; Naess
et al., 1999). T cells are essential for the maintenance of germinal
centers (GCs), where B cells undergo affinity maturation, and
also influence B cell IgG subclass selection (Mayumi et al.,
1983; Vinuesa et al., 2010;Mongini et al., 1981). T follicular helper
cells provide help to B cells within theGC,which differentiate into
short-lived plasma cells, longer-lived plasma cells (LLPCs), or
memory B cells. Only a fraction of GC-derived plasma cells
migrate to the bone marrow, where there is a limited number of
long-term survival niches and competition for residency (Rad-
bruch et al., 2006). The properties pertaining to long-term persis-
tence of plasma cell clones are unclear, but considerable
Table 1. The Overall Variance in Vaccine Responses, Calculated
Using the GREML Method
Vaccine
Measure n VG (SE) VE (SE) VP (SE) VG/VP (SE)
MenC SBA 1,585 0.21 (0.15) 0.54 (0.15) 0.75 (0.03) 0.28 (0.2)
MenC IgG 1,203 0.22 (0.12) 0.24 (0.12) 0.46 (0.02) 0.48 (0.27)
Hib IgG 964 0.05 (0.12) 0.3 (0.12) 0.35 (0.02) 0.14 (0.33)
TT IgG 547 0.21 (0.11) 0.05 (0.11) 0.26 (0.02) 0.81 (0.44)
GREML, genome-based restricted maximum likelihood; VE, residual vari-
ance; VG, genetic variance; VP, phenotypic variance.
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differences between the half-life of serum antibody to different
vaccines (e.g., >200 years for measles and mumps compared
with 10 years for TT) suggest these features are programmed
into plasma cells during their maturation in the GC (Amanna
et al., 2007). We postulate that the lead SNP described here is
causally involved in the generation of competent and competi-
tive (i.e., for long-term survival niches) high-affinity LLPCs, via
an altered TF-binding motif within a hypothetical enhancer
region in antigen-stimulated T cells.
We also identified a region within the HLA gene complex that
contained SNPs associated with the persistence of TT-specific
IgG. HLA molecules present peptides to T cells, which in turn
induce B cells to produce antibodies (Murphy et al., 2008). Given
their role, HLA genes have frequently been candidates in studies
exploring the genetic determinants of vaccine responses
(O’Connor and Pollard, 2013; Mentzer et al., 2015). Moreover,
a GWAS of hepatitis B surface antigen (HBsAg) vaccine-induced
immunity found independent signals across the HLA region
that were associated with HBsAg-specific IgG concentrations
following vaccination (Png et al., 2011). Furthermore, variants
with the HLA-DPB1 locus have been linked to rubella neutraliza-
tion antibody titers following measles-mumps-rubella vaccine,
albeit the association did not reach the customary threshold of
genome-wide significance (lead SNP p = 8.62 3 108) (Lambert
et al., 2015). Interestingly, HLA has been estimated to account
for only aminority of the total heritability associated with humoral
immunity to TT, rubella, and HBV. Yet, to date, no genes outside
the HLA region have been implicated, at the level of genome-
wide significance, with responses to these vaccines. One expla-
nation for this could be a modest individual effect size for these
putative non-HLA loci. Previous studies of immune-related dis-
eases have shown a relationship between the number of loci
Table 2. Top 10 SNPs, Ranked by p Value, Associated with the Persistence of MenC-Specific SBA Titers following Vaccination, in
Combined Analysis (Discovery + Replication Cohort)
CHR SNP Gene Symbol Cohort N Additive Model b Additive Model p Dominant Model b Dominant Model p
20 rs6135736 LOC105369219 discovery 1,436 0.19 (0.12, 0.26) 3.2 3 107 0.24 (0.15, 0.33) 1.2 3 107
replication 915 0.08 (0.01, 0.17) 0.09 0.12 (0.01, 0.22) 0.03
combineda 2,351 0.16 (0.10, 0.22) 6.4 3 108 0.20 (0.14, 0.28) 6.0 3 109b
20 rs4814511 discovery 1,443 0.19 (0.11, 0.26) 3.5 3 107 0.24 (0.15, 0.33) 1.7 3 107
replication 920 0.05 (0.04, 0.13) 0.27 0.09 (0.01, 0.20) 0.08
combineda 2,363 0.14 (0.09, 0.20) 3.7 3 107 0.20 (0.12, 0.27) 1.8 3 108b
20 rs3818168 SIRPG discovery 1,441 0.19 (0.12, 0.27) 2.7 3 107 0.23 (0.14, 0.32) 4.1 3 107
replication 919 0.06 (0.03, 0.14) 0.20 0.11 (0.01, 0.22) 0.04
combineda 2,360 0.15 (0.09, 0.20) 5.9E7 0.19 (0.12, 0.26) 6.2 3 108
20 rs17770331 SIRPG-AS1,
SIRPG
discovery 1,443 0.19 (0.11, 0.26) 5.6 3 107 0.22 (0.13, 0.31) 1.8 3 106
replication 919 0.05 (0.03, 0.14) 0.21 0.09 (0.01, 0.20) 0.07
combineda 2,362 0.14 (0.09, 0.20) 7.3 3 107 0.17 (0.11, 0.25) 4.9 3 107
4 rs10517505 discovery 1,444 0.33 (0.49, 0.17) 7.2 3 105 0.36 (0.53, 0.20) 2.3 3 105
replication 920 0.2359 (0.42, 0.05) 0.01 0.24 (0.43, 0.05) 0.01
combineda 2,364 0.30 (0.42, 0.17) 3.4 3 106 0.32 (0.44, 0.19) 1.2 3 106
20 rs4813191 SIRPG-AS1,
SIRPG
discovery 1,444 0.15 (0.08, 0.22) 1.7 3 105 0.17 (0.09, 0.27) 7.3 3 105
replication 918 0.06 (0.02, 0.14) 0.17 0.10 (0.00, 0.21) 0.04
combineda 2,362 0.12 (0.07, 0.17) 7.8 3 106 0.16 (0.09, 0.228) 4.9 3 106
2 rs1467180 discovery 1,431 0.30 (0.48, 0.14) 4.8 3 104 0.32 (0.50, 0.15) 3.5 3 104
replication 920 0.18 (0.40, 0.05) 0.13 0.18 (0.40, 0.05) 0.13
combineda 2,351 0.27 (0.41, 0.13) 1.5 3 104 0.27 (0.42, 0.14) 1.2 3 104
6 rs551216 ADGRB3 discovery 1,429 0.12 (0.19, 0.05) 2.6 3 104 0.16 (0.25, 0.07) 3.3 3 104
replication 920 0.03 (0.11, 0.05) 0.48 0.10 (0.21, 0.00) 0.05
combineda 2,349 0.08 (0.13, 0.03) 2.7 3 103 0.13 (0.20, 0.06) 2.0 3 104
12 rs1358274 discovery 1,444 0.17 (0.26, 0.09) 9.2 3 105 0.18 (0.28, 0.09) 1.8 3 104
replication 919 0.04 (0.15, 0.06) 0.43 0.07 (0.18, 0.05) 0.28
combineda 2,363 0.13 (0.20, 0.06) 2.3 3 104 0.14 (0.22, 0.07) 2.2 3 104
2 rs2042086 discovery 1,444 0.15 (0.23, 0.07) 1.7 3 104 0.18 (0.28, 0.09) 9.6 3 105
replication 918 0.03 (0.13, 0.05) 0.43 0.04 (0.16, 0.06) 0.4
combineda 2,362 0.11 (0.17, 0.04) 6.8 3 104 0.13 (0.21, 0.06) 2.4 3 104
CHR, chromosome; N, number of participants included in the analysis.
aResults from combining all individual-level data into a single analysis.
bp values <5 3 108 are genome-wide significant.
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reaching genome-wide significance and sample size, and it is
likely that the study of larger vaccinee cohorts will yield more
loci associated with immunity to vaccine antigens (Parkes
et al., 2013). In our study, we estimated the heritability of vac-
cine-induced immunity to vary from 14% to 81%; TT immunity
was estimated to be the most heritable of these measures. Inter-
estingly, analysis of TT immunity required 10 principal compo-
nents (PCs) to regress out genomic inflation, compared with 3
PCs for the other vaccine responses. There are a number of
potential explanations for this finding, including trait heritability,
sample size, linkage disequilibrium structure, and number of
causal variants, which have all been shown to influence genomic
inflation (Yang et al., 2011b).
The identification of causal variants within the HLA region is
intrinsically difficult due to its complex and long-range linkage
disequilibrium structure. The association signals may originate
from differing abilities of classical HLA alleles to bind peptide.
However, it may also be the case that cis-regulatory elements
underlie these associations. To explore this further, we imputed
classical HLA alleles using the discovery stage GWAS dataset
(Dilthey et al., 2011). This analysis suggested HLA-DQB1*0201,
HLA-DRB1*0301, HLA DQB1*0602, and HLA DRB1*1501 were
associated with TT-IgG concentrations. Intriguingly, HLA-
DRB1*0301 is distinct from the other major HLA-DRB1 alleles
both genetically and immunologically, recognizing a peptide
motif that is dissimilar from that recognized by the other major
HLA-DRB1 alleles (Sidney et al., 1992). This allele has also
been associated with increased susceptibility to several autoim-
mune and allergic phenotypes, as well as lower HBsAg-specific
IgG concentrations following hepatitis B vaccine, supporting a
generalizable difference in the peptide-binding preferences
(Alper et al., 1989; Li et al., 2009; Handunnetthi et al., 2010).
The data presented here lend some support to the idea of het-
erogeneous T cell responses to different class II alleles contrib-
uting to the quantitative differences in humoral responses to TT.
The index HLA SNP (rs2523650) remained significantly
associated with TT-IgG concentrations after conditioning for
HLA DRB1*0301, HLA DQB1*0201, HLA DQB1*0602, or HLA
DRB1*1501, suggesting this association is independent of
these classical alleles. Moreover, rs2523650 has been anno-
tated as an expression-trait quantitative locus for HLA-DRB1
and HLA-DRB5 (Zeller et al., 2010). Therefore, these data sup-
port the mechanism underlying this association to be regula-
tory, rather than classical, HLA allele dependent.
Previous studies have shown considerable correlation in im-
mune responses to a number of childhood vaccines (Newport
et al., 2004; Finn et al., 2000; Goldblatt et al., 1999). There
was some thought that this could be largely because of age-
dependent immunological maturation. However, disparities in
the correlations between vaccine antigens contradict a simple
‘‘responsiveness’’ trait (Finn et al., 2000). Nevertheless, it is not
known whether there are pleiotropic loci that are involved in
‘‘vaccine responsiveness’’ in a generic sense. Here, analysis
for pleiotropic loci identified nine genes, at a liberal p value cutoff
of 104, which were shared between two or more measures of
vaccine-induced immunity. Intriguingly, PTPRD was associated
with both MenC-specific SBA titers and PRP-specific IgG con-
centrations, and has previously been associated with rubella-
specific IFN-g responses followingmeasles, mumps, and rubella
(MMR) vaccination (Kennedy et al., 2014). Interestingly, we did
not find any overlap in genes containing the most statistically
associated (p < 1 3 105) SNPs between the vaccine-induced
serological measures. This finding is consistent with data from
the large study into pleiotropic loci among immune-related dis-
eases, which suggested SNPs with the largest effect sizes
tended to be phenotype specific (Parkes et al., 2013).
Table 3. The Results of Combined Analysis for the Five HLA SNPs Selected for Replication Analysis with TT-Specific IgG
Concentrations
CHR SNP Cohort N Additive Model b (95% CI) Additive Model p Dominant Model b (95% CI) Dominant Model p
6 rs2523650 discovery 638 0.12 (0.06, 0.18) 4.1 3 105 0.15 (0.07, 0.22) 9.9 3 105
replication 1,151 0.10 (0.05, 0.14) 2.1 3 105 0.12 (0.05, 0.16) 0.0003
combineda 1,789 0.12 (0.08, 0.15) 2.6 3 1010b 0.14 (0.09, 0.18) 6.5 3 109b
6 rs6903608 discovery 625 0.12 (0.06, 0.18) 4.7 3 105 0.18 (0.10, 0.25) 5.4 3 106
replication 1,096 0.03 (0.02, 0.07) 0.21 0.03 (0.02, 0.09) 0.24
combineda 1,721 0.06 (0.03, 0.10) 2.4 3 104 0.09 (0.04, 0.14) 1.3 3 104
6 rs3094188 discovery 621 0.11 (0.05, 0.16) 2.1 3 104 0.12 (0.04, 0.19) 0.0031
replication 1,108 0.03 (0.01, 0.08) 0.11 0.07 (0.01, 0.13) 0.01
combineda 1,729 0.06 (0.03, 0.10) 4.6 3 104 0.08 (0.04, 0.14) 2.6 3 104
6 rs9268877 discovery 602 0.10 (0.05, 0.16) 1.1 3 104 0.13 (0.05, 0.22) 6.2 3 104
replication 1,094 0.03 (0.01, 0.07) 0.17 0.04 (0.02, 0.10) 0.17
combineda 1,696 0.06 (0.02, 0.09) 0.0012 0.07 (0.02, 0.12) 0.0043
6 rs2523663 discovery 593 0.06 (0.00, 0.12) 0.03 0.08 (0.00, 0.16) 0.04
replication 1,065 0.02 (0.01, 0.07) 0.19 0.01 (0.05, 0.07) 0.67
combineda 1,658 0.04 (0.01, 0.08) 0.0151 0.04 (0.01, 0.09) 0.1178
CHR, chromosome; CI, confidence interval; N, number of participants included in the analysis.
aResults from combining all of the data into a single analysis.
bp < 5 3 108 are genome-wide significant.
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In this study, participants were included from 10 sub-studies,
which differed in terms of age of vaccination, time since vacci-
nation, immunological assay protocols, vaccine schedules
and compositions, and concomitant vaccines administered.
Although these factors were included as covariates in the linear
models, this heterogeneity will have been detrimental to statisti-
cal power (Ioannidis et al., 2009). Of note, there was consider-
able heterogeneity, between the discovery and replication
cohorts, in the effect size estimates for the SNPs with the most
statistical evidence for association with persistence of MenC-
specific SBA titers. Here we report two SNPs associated with
MenC-specific SBA titers, at the level of genome-wide signifi-
cance, based on combining individual-level data from all
cohorts; although this results in increased power (compared
with meta-analysis), the caveat is that this approach is more
susceptible to inflated error rates or loss of power when there
is heterogeneity between cohorts (Skol et al., 2006). Neverthe-
less, the SNP with the most statistical evidence for association
with the persistence of MenC-specific SBA titers showed evi-
dence of replication (p value < 0.05) in the replication cohort
and a meta-analysis p value of 5.1 3 108.
No SNPs were found to be associated with PRP-specific IgG
concentrations at the level of genome-wide significance, an
observation that could have a number of possible explanations.
The statistical power to identify SNPs associated with quantita-
tive traits is influenced by variant effect size, the number and fre-
quency of causal variants, sample size, as well as the robustness
of the phenotypic measure (Manchia et al., 2013; Shin and Lee,
2015). Of note, the PRP-specific IgG assessments described
here were made in several laboratories, and problems with in-
ter-assay standardization of PRP-specific IgG quantification
have been described (Kelly et al., 2004). Moreover, although
Hib carriage rates have been extremely low in the United
Kingdom for the last decade among preschool children, older
participants, in particular, may have been exposed to Hib coloni-
zation in the pre-vaccine era, when carriage rates in young
children were up to 8% (McVernon et al., 2004). Equally,
polysaccharides cross-reactive with the Hib polysaccharide,
PRP, are present on several bacterial species, such that the
rate of immunizing exposures (Hib or cross-reactive bacteria) is
estimated to be 1.2 per year per child, even in the post-vaccina-
tion era (Leino et al., 2002). Phenotypical variance introduced by
measurement variability and immunological boosting, because
of natural exposure, may have severely diminished statistical po-
wer to detect genetic variants associated with the persistence of
PRP-specific IgG.
Because these data were limited to Caucasians from the
United Kingdom and the Netherlands, it is unclear how these
would relate to other ethnic populations, especially considering
the allelic frequency of the lead SNP proximal to SIRPG varies
drastically between HapMap populations: European ancestry
(CEU) minor allele frequency (MAF) 20% and Sub-Saharan
Africans (YRI) MAF 1%. Conversely, the future use of trans-
ethnic vaccine cohorts, such as those described by Mentzer
et al. (2015), may leverage different linkage equilibrium patterns
to help fine-map causal variants. Even though GWAS captures
common variation adequately, it does not capture rare variants
efficiently (i.e., MAF < 1%). This may be particularly relevant
because rare variants of large effect sizes may conceivably
contribute to the ‘‘extremes’’ of vaccine responsiveness (e.g.,
vaccine failure). Next-generation sequencing approaches are
more conducive to the description of rare variants; however,
the cost of these approaches often precludes their use. In
this study, we described genetic variants associated with the
persistence of immunity following immunization. However, the
absence of data from the acute vaccine response (peaking at
about 1 month post-vaccination) meant we could not differen-
tiate individuals who responded poorly (‘‘primary vaccine fail-
ures’’) from those who failed to maintain serological immunity
(‘‘secondary vaccine failures’’).
Currently, we are not aware of any implemented healthcare
system to identify children whose vaccine-induced immunity
has waned and would benefit from additional immunizations. In
fact, the additional healthcare provision required for such a sys-
tem might make it unfeasible in many settings. Conversely, we
envisage genetic markers of vaccine responses could soon prove
their clinical utility. Although the cost of whole-genome
sequencing is constantly decreasing, our understanding of these
data and their clinical utility has been rapidly rising (Khera et al.,
2018). It is realistic to conceive that neonatal screening
Table 4. Top 10 Imputed Human Leukocyte Antigen Alleles, Based upon p Values, in Association Analysis with TT-Specific IgG
Concentrations in Discovery Stage
CHR SNP N Additive Model b (95% CI) Additive Model p Dominant Model b (95% CI) Dominant Model p
6 HLA_DRB1_03 535 0.19 (0.28, 0.11) 1.42 3 105a 0.18 (0.28, 0.09) 1.75 3 104a
6 HLA_DRB1_0301 535 0.19 (0.28, 0.11) 1.42 3 105a 0.18 (0.28, 0.09) 1.75 3 104a
6 HLA_DQB1_0201 535 0.18 (0.27, 0.09) 5.46 3 105a 0.17 (0.27, 0.07) 6.35 3 104
6 HLA_DQB1_02 535 0.14 (0.21, 0.07) 5.91 3 105a 0.17 (0.26, 0.08) 1.10 3 104a
6 HLA_DRB1_1501 535 0.15 (0.07, 0.24) 5.31 3 104 0.20 (0.10, 0.30) 9.02 3 105a
6 HLA_DRB1_15 535 0.14 (0.06, 0.23) 8.87 3 104 0.19 (0.10, 0.29) 1.08 3 104a
6 HLA_DQB1_0602 535 0.15 (0.06, 0.23) 1.08 3 103 0.18 (0.08, 0.28) 2.88 3 104a
6 HLA_A_0201 535 0.11 (0.18, 0.04) 1.26 3 103 0.13 (0.21, 0.043) 3.32 3 103
6 HLA_DQA1_01 535 0.10 (0.04, 0.16) 1.58 3 103 0.10 (0.01, 0.19) 2.50 3 102
6 HLA_A_24 535 0.19 (0.07, 0.32) 2.32 3 103 0.18 (0.04, 0.31) 8.88 3 103
CHR, chromosome; CI, confidence interval; N, number of participants included in the analysis.
ap < 3 3 104 (0.05/168).
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approaches will soon incorporate a number of genetic risk factors
(potentially derived the whole-genome sequencing at birth) (Ho-
ward et al., 2015). Therefore, it is feasible that in the near future
that the persistence of immunity could be predicted and vaccine
regimens personalized to maximize vaccine effectiveness.
The modest effect size of the genetic associations described
in this study are consistent with the hypothesis that the genetic
variants most strongly associated with complex phenotypes
typically account for only a small fraction of the genetic variance;
many additional causal loci, with small effect sizes, explain much
of the trait heritability (Manolio et al., 2009; Yang et al., 2013).
Also, a number of other host factors such as age, nutritional sta-
tus, microbiota, and infectious diseases have been shown to
influence immune responses (Kampmann and Jones, 2015).
For example, some acute viral infections have been shown to
have profound immunomodulatory effects, long after symptom-
atic recovery (Mina et al., 2015; Huang and Hong, 1973). Natu-
rally acquired immunity, and immunological boosting through
natural exposure, may also strongly influence immunity to organ-
isms against which children are vaccinated (Andrews et al.,
2015; Wilson et al., 2017; Voysey et al., 2017). However, this is
not likely to have played a major role in immunity to the vaccines
studied here; during the time frame of this study, carriage rates
for Hib and MenC were very low in young children, and tetanus
is non-communicable (McVernon et al., 2004; Maiden et al.,
2008). Age at vaccination is known to influence vaccine re-
sponses; although we included this in linear regression analysis,
heterogeneity in age of vaccination will have been detrimental
to study power (Snape et al., 2008a; Tang et al., 2015).
Moreover, twin-twin variability in a number of immune system
parameters has been shown to increase with age, suggesting
GWAS studies focused on vaccine responses early in life may
have the greatest statistical power (Brodin et al., 2015). Here
we assessed genetics factors with generalizable effects on
vaccine responses, notwithstanding there may also be sex-
dependent factors that influence immune responses to vaccines
(Klein et al., 2015).
Figure 2. Manhattan Plots of p Values from
Regression Analyses between SNPs and
log10-Transformed Vaccine-Induced Immu-
nological Measures
(A–D) Manhattan plots of p values from regression
analyses between SNPs and log10-transformed
vaccine-induced immunological measure: (A)
MenC-specific IgG concentrations (n = 1,203), (B)
MenC-specific SBA titers (n = 1,585), (C) PRP-
specific IgG concentrations (n = 964), and (D)
TT-specific IgG concentrations (n = 547). The
horizontal blue line represents the level of sug-
gestive statistical association (p < 1 3 105), and
the horizontal red line denotes the level of genome-
wide statistical significance (p < 5 3 108).
In conclusion, we describe a GWAS of
the persistence of immunity to three
routine childhood vaccines. We detail two
loci that were associated with the persis-
tence of vaccine-induced immunity, at
the level of genome-wide significance. Although these variants
inevitably account for only a small portion of the total genetically
determinedcontribution topersistenceof vaccine-induced immu-
nity, this study demonstrates the utility of applying this ‘‘hypothe-
sis-free’’ approach in generating candidates for future functional
and mechanistic investigations, the description of which may ulti-
mately influence vaccine development and implementation.
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Data are included from the discovery stage GWAS of persistence of MenC-specific IgG concentrations (n = 1,203), MenC-specific serum bactericidal titers
(n = 1,585), PRP-specific IgG concentrations (n = 964), and TT-specific IgG concentrations (n = 547). Genes that are associated (p < 13 104) with more than the
serological measures assessed are highlighted with links. This diagram was generated using Circos (http://circos.ca/).
Cell Reports 27, 3241–3253, June 11, 2019 3249
Received: October 22, 2018
Revised: January 25, 2019
Accepted: May 15, 2019
Published: June 11, 2019
REFERENCES
1000 Genomes Project Consortium; Abecasis, G.R., Auton, A., Brooks, L.D.,
DePristo, M.A., Durbin, R.M., Handsaker, R.E., Kang, H.M., Marth, G.T., and
McVean, G.A. (2012). An integratedmap of genetic variation from 1,092 human
genomes. Nature 491, 56–65.
Alper, C.A., Kruskall, M.S., Marcus-Bagley, D., Craven, D.E., Katz, A.J., Brink,
S.J., Dienstag, J.L., Awdeh, Z., and Yunis, E.J. (1989). Genetic prediction of
nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321, 708–712.
Amanna, I.J., Carlson, N.E., and Slifka, M.K. (2007). Duration of humoral immu-
nity to common viral and vaccine antigens. N. Engl. J. Med. 357, 1903–1915.
Anderson, C.A., Pettersson, F.H., Clarke, G.M., Cardon, L.R., Morris, A.P., and
Zondervan, K.T. (2010). Data quality control in genetic case-control associa-
tion studies. Nat. Protoc. 5, 1564–1573.
Andrews, S.F., Kaur, K., Pauli, N.T., Huang, M., Huang, Y., and Wilson, P.C.
(2015). High preexisting serological antibody levels correlate with diversifica-
tion of the influenza vaccine response. J. Virol. 89, 3308–3317.
Aulchenko, Y.S., Ripke, S., Isaacs, A., and van Duijn, C.M. (2007). GenABEL:
an R library for genome-wide association analysis. Bioinformatics 23, 1294–
1296.
Barclay, A.N., and Brown, M.H. (2006). The SIRP family of receptors and im-
mune regulation. Nat. Rev. Immunol. 6, 457–464.
Black, S.B., Shinefield, H.R., Fireman, B., Hiatt, R., Polen, M., and Vittinghoff,
E.; The Northern California Kaiser Permanente Vaccine Study Center Pediat-
rics Group (1991). Efficacy in infancy of oligosaccharide conjugate Haemophi-
lus influenzae type b (HbOC) vaccine in a United States population of 61,080
children. Pediatr. Infect. Dis. J. 10, 97–104.
Blanchard-Rohner, G., Snape, M.D., Kelly, D.F., O’Connor, D., John, T., Kib-
wana, E., Parks, H., Ford, K., Dull, P.M., and Pollard, A.J. (2013). Seropreva-
lence and placental transmission of maternal antibodies specific for Neisseria
meningitidis Serogroups A, C, Y and W135 and influence of maternal
antibodies on the immune response to a primary course of MenACWY-CRM
vaccine in the United Kingdom. Pediatr. Infect. Dis. J. 32, 768–776.
Booy, R., Taylor, S.A., Dobson, S.R., Isaacs, D., Sleight, G., Aitken, S., Grif-
fiths, H., Chapel, H., Mayon-White, R.T., Macfarlane, J.A., et al. (1992). Immu-
nogenicity and safety of PRP-T conjugate vaccine given according to the
British accelerated immunisation schedule. Arch. Dis. Child. 67, 475–478.
Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C.J., Furman, D., Shen-
Orr, S., Dekker, C.L., Swan, G.E., Butte, A.J., et al. (2015). Variation in the
human immune system is largely driven by non-heritable influences. Cell
160, 37–47.
Brooke, G., Holbrook, J.D., Brown, M.H., and Barclay, A.N. (2004). Human
lymphocytes interact directly with CD47 through a novel member of the signal
regulatory protein (SIRP) family. J. Immunol. 173, 2562–2570.
Coetzee, S.G., Coetzee, G.A., and Hazelett, D.J. (2015). motifbreakR: an
R/Bioconductor package for predicting variant effects at transcription factor
binding sites. Bioinformatics 31, 3847–3849.
Collins, C.L., Salt, P., McCarthy, N., Chantler, T., Lane, L., Hemme, F., Diggle,
L., Buttery, J., Kitchin, N.R., Moxon, E.R., and Pollard, A.J. (2004). Immunoge-
nicity and safety of a low-dose diphtheria, tetanus and acellular pertussis com-
bination vaccine with either inactivated or oral polio vaccine as a pre-school
booster in UK children. Vaccine 22, 4262–4269.
Dai, H., Friday, A.J., Abou-Daya, K.I., Williams, A.L., Mortin-Toth, S., Nicotra,
M.L., Rothstein, D.M., Shlomchik, W.D., Matozaki, T., Isenberg, J.S., et al.
(2017). Donor SIRPa polymorphism modulates the innate immune response
to allogeneic grafts. Sci. Immunol. 2, eaam6202.
Davila, S., Froeling, F.E., Tan, A., Bonnard, C., Boland, G.J., Snippe, H., Hib-
berd, M.L., and Seielstad, M. (2010). New genetic associations detected in a
host response study to hepatitis B vaccine. Genes Immun. 11, 232–238.
de Voer, R.M., Schepp, R.M., Versteegh, F.G., van der Klis, F.R., and Berbers,
G.A. (2009). Simultaneous detection of Haemophilus influenzae type b poly-
saccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y,
and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based
multiplex immunoassay. Clin. Vaccine Immunol. 16, 433–436.
de Voer, R.M., Mollema, L., Schepp, R.M., de Greeff, S.C., van Gageldonk,
P.G., de Melker, H.E., Sanders, E.A., Berbers, G.A., and van der Klis, F.R.
(2010). Immunity against Neisseria meningitidis serogroup C in the Dutch
population before and after introduction of the meningococcal c conjugate
vaccine. PLoS ONE 5, e12144.
Delaneau, O., Zagury, J.F., and Marchini, J. (2013). Improved whole-chromo-
some phasing for disease and population genetic studies. Nat. Methods 10,
5–6.
Dilthey, A.T., Moutsianas, L., Leslie, S., andMcVean, G. (2011). HLA*IMP—san
integrated framework for imputing classical HLA alleles from SNP genotypes.
Bioinformatics 27, 968–972.
Finn, A., Blondeau, C., and Bell, F. (2000). Haemophilus influenzae type B (Hib)
antibody responses in children given diphtheria-tetanus-acellular pertussis-
Hib combination vaccines. J. Infect. Dis. 181, 2117–2118.
GBD 2013 Mortality and Causes of Death Collaborators (2015). Global,
regional, and national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: a systematic analysis for the Global
Burden of Disease Study 2013. Lancet 385, 117–171.
Gheesling, L.L., Carlone, G.M., Pais, L.B., Holder, P.F., Maslanka, S.E., Plikay-
tis, B.D., Achtman,M., Densen, P., Frasch, C.E., Ka¨yhty, H., et al. (1994). Multi-
center comparison of Neisseria meningitidis serogroup C anti-capsular
polysaccharide antibody levels measured by a standardized enzyme-linked
immunosorbent assay. J. Clin. Microbiol. 32, 1475–1482.
Goldblatt, D., Richmond, P., Millard, E., Thornton, C., and Miller, E. (1999). The
induction of immunologic memory after vaccination with Haemophilus influen-
zae type b conjugate and acellular pertussis-containing diphtheria, tetanus,
and pertussis vaccine combination. J. Infect. Dis. 180, 538–541.
Handunnetthi, L., Ramagopalan, S.V., Ebers, G.C., and Knight, J.C. (2010).
Regulation of major histocompatibility complex class II gene expression,
genetic variation and disease. Genes Immun. 11, 99–112.
Howard, H.C., Knoppers, B.M., Cornel, M.C., Wright Clayton, E., Se´ne´cal, K.,
and Borry, P.European Society of Human Genetics; P3G International Paediat-
ric Platform; Human Genome Organisation; PHG Foundation (2015). Whole-
genome sequencing in newborn screening? A statement on the continued
importance of targeted approaches in newborn screening programmes. Eur.
J. Hum. Genet. 23, 1593–1600.
Howie, B.N., Donnelly, P., and Marchini, J. (2009). A flexible and accurate ge-
notype imputationmethod for the next generation of genome-wide association
studies. PLoS Genet. 5, e1000529.
Huang, S.W., and Hong, R. (1973). Lymphopenia and multiple viral infections.
JAMA 225, 1120–1121.
Ioannidis, J.P., Thomas, G., and Daly, M.J. (2009). Validating, augmenting and
refining genome-wide association signals. Nat. Rev. Genet. 10, 318–329.
Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.M., Concannon, P.J., Rich,
S.S., Raychaudhuri, S., and de Bakker, P.I. (2013). Imputing amino acid poly-
morphisms in human leukocyte antigens. PLoS ONE 8, e64683.
Kampmann, B., and Jones, C.E. (2015). Factors influencing innate immunity
and vaccine responses in infancy. Philos. Trans. R. Soc. Lond. B Biol. Sci.
370, 20140148.
Kelly, D.F., Moxon, E.R., and Pollard, A.J. (2004). Haemophilus influenzae type
b conjugate vaccines. Immunology 113, 163–174.
Kennedy, R.B., Ovsyannikova, I.G., Haralambieva, I.H., Lambert, N.D., Pan-
kratz, V.S., and Poland, G.A. (2014). Genome-wide SNP associations with
rubella-specific cytokine responses in measles-mumps-rubella vaccine
recipients. Immunogenetics 66, 493–499.
Khatami, A., Peters, A., Robinson, H., Williams, N., Thompson, A., Findlow, H.,
Pollard, A.J., and Snape, M.D. (2011). Maintenance of immune response
3250 Cell Reports 27, 3241–3253, June 11, 2019
throughout childhood following serogroup C meningococcal conjugate vacci-
nation in early childhood. Clin. Vaccine Immunol. 18, 2038–2042.
Khatami, A., Clutterbuck, E.A., Thompson, A.J., McKenna, J.A., Pace, D.,
Birks, J., Snape, M.D., and Pollard, A.J. (2014). Evaluation of the induction
of immune memory following infant immunisation with serogroup C Neisseria
meningitidis conjugate vaccines—exploratory analyses within a randomised
controlled trial. PLoS ONE 9, e101672.
Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Na-
tarajan, P., Lander, E.S., Lubitz, S.A., Ellinor, P.T., and Kathiresan, S. (2018).
Genome-wide polygenic scores for common diseases identify individuals
with risk equivalent to monogenic mutations. Nat. Genet. 50, 1219–1224.
Klein, S.L., Marriott, I., and Fish, E.N. (2015). Sex-based differences in immune
function and responses to vaccination. Trans. R. Soc. Trop. Med. Hyg. 109,
9–15.
Kollmann, T.R. (2013). Variation between Populations in the Innate Immune
Response to Vaccine Adjuvants. Front. Immunol. 4, 81.
Lambert, N.D., Haralambieva, I.H., Kennedy, R.B., Ovsyannikova, I.G., Pan-
kratz, V.S., and Poland, G.A. (2015). Polymorphisms in HLA-DPB1 are
associated with differences in rubella virus-specific humoral immunity after
vaccination. J. Infect. Dis. 211, 898–905.
Lee, L.A., Franzel, L., Atwell, J., Datta, S.D., Friberg, I.K., Goldie, S.J., Reef,
S.E., Schwalbe, N., Simons, E., Strebel, P.M., et al. (2013). The estimated mor-
tality impact of vaccinations forecast to be administered during 2011-2020 in
73 countries supported by the GAVI Alliance. Vaccine 31 (Suppl 2), B61–B72.
Leino, T., Auranen, K., Ma¨kela¨, P.H., Ka¨yhty, H., Ramsay, M., Slack, M., and
Takala, A.K. (2002). Haemophilus influenzae type b and cross-reactive
antigens in natural Hib infection dynamics; modelling in two populations.
Epidemiol. Infect. 129, 73–83.
Li, Y., Ni, R., Song, W., Shao, W., Shrestha, S., Ahmad, S., Cunningham, C.K.,
Flynn, P.M., Kapogiannis, B.G., Wilson, C.M., and Tang, J. (2009). Clear and
independent associations of several HLA-DRB1 alleles with differential
antibody responses to hepatitis B vaccination in youth. Hum. Genet. 126,
685–696.
Maiden, M.C., Ibarz-Pavo´n, A.B., Urwin, R., Gray, S.J., Andrews, N.J., Clarke,
S.C., Walker, A.M., Evans, M.R., Kroll, J.S., Neal, K.R., et al. (2008). Impact of
meningococcal serogroup C conjugate vaccines on carriage and herd immu-
nity. J. Infect. Dis. 197, 737–743.
Manchia, M., Cullis, J., Turecki, G., Rouleau, G.A., Uher, R., and Alda, M.
(2013). The impact of phenotypic and genetic heterogeneity on results of
genome wide association studies of complex diseases. PLoS ONE 8, e76295.
Manolio, T.A., Collins, F.S., Cox, N.J., Goldstein, D.B., Hindorff, L.A., Hunter,
D.J., McCarthy, M.I., Ramos, E.M., Cardon, L.R., Chakravarti, A., et al.
(2009). Finding the missing heritability of complex diseases. Nature 461,
747–753.
Marchini, J., and Howie, B. (2010). Genotype imputation for genome-wide
association studies. Nat. Rev. Genet. 11, 499–511.
Maslanka, S.E., Gheesling, L.L., Libutti, D.E., Donaldson, K.B., Harakeh, H.S.,
Dykes, J.K., Arhin, F.F., Devi, S.J., Frasch, C.E., Huang, J.C., et al.; The Multi-
laboratory StudyGroup (1997). Standardization and amultilaboratory compar-
ison of Neisseria meningitidis serogroup A and C serum bactericidal assays.
Clin. Diagn. Lab. Immunol. 4, 156–167.
Maurano, M.T., Humbert, R., Rynes, E., Thurman, R.E., Haugen, E., Wang, H.,
Reynolds, A.P., Sandstrom, R., Qu, H., Brody, J., et al. (2012). Systematic
localization of common disease-associated variation in regulatory DNA.
Science 337, 1190–1195.
Mayumi, M., Kuritani, T., Kubagawa, H., and Cooper, M.D. (1983). IgG sub-
class expression by human B lymphocytes and plasma cells: B lymphocytes
precommitted to IgG subclass can be preferentially induced by polyclonal mi-
togens with T cell help. J. Immunol. 130, 671–677.
McVernon, J., Johnson, P.D., Pollard, A.J., Slack, M.P., and Moxon, E.R.
(2003). Immunologic memory in Haemophilus influenzae type b conjugate vac-
cine failure. Arch. Dis. Child. 88, 379–383.
McVernon, J., Howard, A.J., Slack, M.P., and Ramsay, M.E. (2004). Long-term
impact of vaccination on Haemophilus influenzae type b (Hib) carriage in the
United Kingdom. Epidemiol. Infect. 132, 765–767.
Mentzer, A.J., O’Connor, D., Pollard, A.J., and Hill, A.V. (2015). Searching for
the human genetic factors standing in theway of universally effective vaccines.
Philos. Trans. R. Soc. Lond. B Biol. Sci. 370, 20140341.
Michaelsen, T.E., Garred, P., and Aase, A. (1991). Human IgG subclass pattern
of inducing complement-mediated cytolysis depends on antigen concentra-
tion and to a lesser extent on epitope patchiness, antibody affinity and comple-
ment concentration. Eur. J. Immunol. 21, 11–16.
Miller, E., Salisbury, D., and Ramsay, M. (2001). Planning, registration, and im-
plementation of an immunisation campaign against meningococcal serogroup
C disease in the UK: a success story. Vaccine 20 (Suppl 1), S58–S67.
Mina, M.J., Metcalf, C.J., de Swart, R.L., Osterhaus, A.D., and Grenfell, B.T.
(2015). Long-term measles-induced immunomodulation increases overall
childhood infectious disease mortality. Science 348, 694–699.
Mongini, P.K., Stein, K.E., and Paul, W.E. (1981). T cell regulation of IgG sub-
class antibody production in response to T-independent antigens. J. Exp.
Med. 153, 1–12.
Murphy, K.P., Travers, P., Walport, M., Ehrenstein, M., and Janeway, C.A.
(2008). Janeway’s Immunobiology (Garland Science).
Naess, L.M., Aarvak, T., Aase, A., Oftung, F., Høiby, E.A., Sandin, R., and Mi-
chaelsen, T.E. (1999). Human IgG subclass responses in relation to serum
bactericidal and opsonic activities after immunization with three doses of the
Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
Vaccine 17, 754–764.
Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining,
W.N., Means, A.R., Kasturi, S.P., Khan, N., Li, G.M., et al. (2011). Systems
biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12,
786–795.
Nettleship, J.E., Ren, J., Scott, D.J., Rahman, N., Hatherley, D., Zhao, Y., Stu-
art, D.I., Barclay, A.N., and Owens, R.J. (2013). Crystal structure of signal reg-
ulatory protein gamma (SIRPg) in complex with an antibody Fab fragment.
BMC Struct. Biol. 13, 13.
Newport, M.J., Goetghebuer, T., Weiss, H.A., Whittle, H., Siegrist, C.A., and
Marchant, A.; MRC Gambia Twin Study Group (2004). Genetic regulation of
immune responses to vaccines in early life. Genes Immun. 5, 122–129.
Nguyen, Q.N., Himes, J.E., Martinez, D.R., and Permar, S.R. (2016). The
Impact of the GutMicrobiota on Humoral Immunity to Pathogens and Vaccina-
tion in Early Infancy. PLoS Pathog. 12, e1005997.
O’Connor, D., and Pollard, A.J. (2013). Characterizing vaccine responses us-
ing host genomic and transcriptomic analysis. Clin. Infect. Dis. 57, 860–869.
O’Connor, D., Moore, C.E., Snape, M.D., John, T., Hill, A.V., and Pollard, A.J.
(2014). Exonic single nucleotide polymorphisms within TLR3 associated with
infant responses to serogroup C meningococcal conjugate vaccine. Vaccine
32, 3424–3430.
O’Connor, D., Clutterbuck, E.A., Thompson, A.J., Snape, M.D., Ramasamy,
M.N., Kelly, D.F., and Pollard, A.J. (2017). High-dimensional assessment of
B-cell responses to quadrivalent meningococcal conjugate and plain polysac-
charide vaccine. Genome Med. 9, 11.
Oh, S.Y., Griffiths, D., John, T., Lee, Y.C., Yu, L.M., McCarthy, N., Heath, P.T.,
Crook, D., Ramsay, M., Moxon, E.R., and Pollard, A.J. (2008). School-aged
children: a reservoir for continued circulation of Haemophilus influenzae type
b in the United Kingdom. J. Infect. Dis. 197, 1275–1281.
Pace, D., Snape, M., Westcar, S., Hamaluba, M., Yu, L.M., Begg, N., Wysocki,
J., Czajka, H., Maechler, G., Boutriau, D., and Pollard, A.J. (2007). A new com-
bination haemophilus influenzae type B and Neisseria meningitidis serogroup
C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pe-
diatr. Infect. Dis. J. 26, 1057–1059.
Pace, D., Khatami, A., McKenna, J., Campbell, D., Attard-Montalto, S., Birks,
J., Voysey, M., White, C., Finn, A., Macloed, E., et al. (2015). Immunogenicity of
reduced dose priming schedules of serogroup C meningococcal conjugate
Cell Reports 27, 3241–3253, June 11, 2019 3251
vaccine followed by booster at 12 months in infants: open label randomised
controlled trial. BMJ 350, h1554.
Parkes, M., Cortes, A., van Heel, D.A., and Brown, M.A. (2013). Genetic in-
sights into common pathways and complex relationships among immune-
mediated diseases. Nat. Rev. Genet. 14, 661–673.
Perrett, K.P., Winter, A.P., Kibwana, E., Jin, C., John, T.M., Yu, L.M., Borrow,
R., Curtis, N., and Pollard, A.J. (2010). Antibody persistence after serogroup C
meningococcal conjugate immunization of United Kingdom primary-school
children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Clin. Infect. Dis. 50, 1601–1610.
Piccio, L., Vermi, W., Boles, K.S., Fuchs, A., Strader, C.A., Facchetti, F., Cella,
M., and Colonna, M. (2005). Adhesion of human T cells to antigen-presenting
cells through SIRPbeta2-CD47 interaction costimulates T-cell proliferation.
Blood 105, 2421–2427.
Pickering, J.W., Martins, T.B., Schroder, M.C., and Hill, H.R. (2002). Compar-
ison of a multiplex flow cytometric assay with enzyme-linked immunosorbent
assay for auantitation of antibodies to tetanus, diphtheria, and Haemophilus
influenzae Type b. Clin. Diagn. Lab. Immunol. 9, 872–876.
Png, E., Thalamuthu, A., Ong, R.T., Snippe, H., Boland, G.J., and Seielstad, M.
(2011). A genome-wide association study of hepatitis B vaccine response in an
Indonesian population reveals multiple independent risk variants in the HLA re-
gion. Hum. Mol. Genet. 20, 3893–3898.
Pollard, A.J., Perrett, K.P., and Beverley, P.C. (2009). Maintaining protection
against invasive bacteria with protein-polysaccharide conjugate vaccines.
Nat. Rev. Immunol. 9, 213–220.
Price, A.L., Patterson, N.J., Plenge, R.M., Weinblatt, M.E., Shadick, N.A., and
Reich, D. (2006). Principal components analysis corrects for stratification in
genome-wide association studies. Nat. Genet. 38, 904–909.
Public Health England (2014). Changes to the meningococcal C conjugate
(MenC) vaccine schedule 2013-2015 (PHE publications), gateway
no. 2013458. https://assets.publishing.service.gov.uk/government/uploads/
system/uploads/attachment_data/file/336171/MenC_information_for_health
care_professionals_V7_.pdf.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D.,
Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., and Sham, P.C. (2007). PLINK:
a tool set for whole-genome association and population-based linkage ana-
lyses. Am. J. Hum. Genet. 81, 559–575.
Radbruch, A., Muehlinghaus, G., Luger, E.O., Inamine, A., Smith, K.G., Do¨rner,
T., and Hiepe, F. (2006). Competence and competition: the challenge of
becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741–750.
Romanoski, C.E., Glass, C.K., Stunnenberg, H.G., Wilson, L., and Almouzni, G.
(2015). Epigenomics: Roadmap for regulation. Nature 518, 314–316.
Salisbury, D., Ramsay, M., and Noakes, K. (2014). Immunisation Against Infec-
tious Disease (The Green Book).
Savy, M., Edmond, K., Fine, P.E., Hall, A., Hennig, B.J., Moore, S.E., Mulhol-
land, K., Schaible, U., and Prentice, A.M. (2009). Landscape analysis of inter-
actions between nutrition and vaccine responses in children. J. Nutr. 139,
2154S–2218S.
Seiffert, M., Brossart, P., Cant, C., Cella, M., Colonna, M., Brugger, W., Kanz,
L., Ullrich, A., and B€uhring, H.J. (2001). Signal-regulatory protein alpha (SIR-
Palpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with
high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic
cells. Blood 97, 2741–2749.
Shin, J., and Lee, C. (2015). Statistical power for identifying nucleotidemarkers
associatedwith quantitative traits in genome-wide association analysis using a
mixed model. Genomics 105, 1–4.
Sidney, J., Oseroff, C., Southwood, S., Wall, M., Ishioka, G., Koning, F., and
Sette, A. (1992). DRB1*0301 molecules recognize a structural motif distinct
from the one recognized by most DR beta 1 alleles. J. Immunol. 149, 2634–
2640.
Siegrist, C.A., and Aspinall, R. (2009). B-cell responses to vaccination at the
extremes of age. Nat. Rev. Immunol. 9, 185–194.
Skol, A.D., Scott, L.J., Abecasis, G.R., and Boehnke, M. (2006). Joint analysis
is more efficient than replication-based analysis for two-stage genome-wide
association studies. Nat. Genet. 38, 209–213.
Snape, M.D., Kelly, D.F., Salt, P., Green, S., Snowden, C., Diggle, L., Borkow-
ski, A., Yu, L.M., Moxon, E.R., and Pollard, A.J. (2006). Serogroup C meningo-
coccal glycoconjugate vaccine in adolescents: persistence of bactericidal
antibodies and kinetics of the immune response to a booster vaccine more
than 3 years after immunization. Clin. Infect. Dis. 43, 1387–1394.
Snape, M.D., Kelly, D.F., Lewis, S., Banner, C., Kibwana, L., Moore, C.E., Dig-
gle, L., John, T., Yu, L.M., Borrow, R., et al. (2008a). Seroprotection against
serogroup C meningococcal disease in adolescents in the United Kingdom:
observational study. BMJ 336, 1487–1491.
Snape, M.D., Perrett, K.P., Ford, K.J., John, T.M., Pace, D., Yu, L.M., Langley,
J.M., McNeil, S., Dull, P.M., Ceddia, F., et al. (2008b). Immunogenicity of a
tetravalent meningococcal glycoconjugate vaccine in infants: a randomized
controlled trial. JAMA 299, 173–184.
Snape, M.D., Klinger, C.L., Daniels, E.D., John, T.M., Layton, H., Rollinson, L.,
Pestridge, S., Dymond, S., Galiza, E., Tansey, S., et al. (2010). Immunogenicity
and reactogenicity of a 13-valent-pneumococcal conjugate vaccine adminis-
tered at 2, 4, and 12 months of age: a double-blind randomized active-
controlled trial. Pediatr. Infect. Dis. J. 29, e80–e90.
Tang, Y., Plikaytis, B.D., Preziosi, M.P., and Borrow, R. (2015). Influence of
Age on Antibody Response and Persistence Following Immunization With
MenAfriVac. Clin. Infect. Dis. 61 (Suppl 5), S531–S539.
Trotter, C.L., McVernon, J., Andrews, N.J., Burrage, M., and Ramsay, M.E.
(2003). Antibody to Haemophilus influenzae type b after routine and catch-
up vaccination. Lancet 361, 1523–1524.
van den Berg, T.K., Yoder, J.A., and Litman, G.W. (2004). On the origins of
adaptive immunity: innate immune receptors join the tale. Trends Immunol.
25, 11–16.
Vinuesa, C.G., Linterman, M.A., Goodnow, C.C., and Randall, K.L. (2010). T
cells and follicular dendritic cells in germinal center B-cell formation and selec-
tion. Immunol. Rev. 237, 72–89.
Visscher, P.M., Wray, N.R., Zhang, Q., Sklar, P., McCarthy, M.I., Brown, M.A.,
and Yang, J. (2017). 10 Years of GWAS Discovery: Biology, Function, and
Translation. Am. J. Hum. Genet. 101, 5–22.
Voysey, M., Kelly, D.F., Fanshawe, T.R., Sadarangani, M., O’Brien, K.L., Per-
era, R., and Pollard, A.J. (2017). The Influence of Maternally Derived Antibody
and Infant Age at Vaccination on Infant Vaccine Responses: An Individual
Participant Meta-analysis. JAMA Pediatr. 171, 637–646.
Waddington, C.S., Walker, W.T., Oeser, C., Reiner, A., John, T., Wilkins, S.,
Casey, M., Eccleston, P.E., Allen, R.J., Okike, I., et al. (2010). Safety and
immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted
whole virion H1N1 influenza vaccine in UK children aged 6 months-12
years: open label, randomised, parallel group, multicentre study. BMJ
340, c2649.
Ward, L.D., and Kellis, M. (2012). HaploReg: a resource for exploring chro-
matin states, conservation, and regulatory motif alterations within sets of
genetically linked variants. Nucleic Acids Res. 40, D930–D934.
Watt, J.P., Wolfson, L.J., O’Brien, K.L., Henkle, E., Deloria-Knoll, M., McCall,
N., Lee, E., Levine, O.S., Hajjeh, R., Mulholland, K., and Cherian, T.; Hib and
Pneumococcal Global Burden of Disease Study Team (2009). Burden of dis-
ease caused by Haemophilus influenzae type b in children younger than 5
years: global estimates. Lancet 374, 903–911.
Wellcome Trust Case Control Consortium (2007). Genome-wide association
study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 447, 661–678.
Wilder-Smith, A., and Memish, Z. (2003). Meningococcal disease and travel.
Int. J. Antimicrob. Agents 21, 102–106.
Wilson, R., Cohen, J.M., Reglinski, M., Jose, R.J., Chan, W.Y., Marshall, H., de
Vogel, C., Gordon, S., Goldblatt, D., Petersen, F.C., et al. (2017). Naturally
Acquired Human Immunity to Pneumococcus Is Dependent on Antibody to
Protein Antigens. PLoS Pathog. 13, e1006137.
3252 Cell Reports 27, 3241–3253, June 11, 2019
World Health Organization (2017). Immunization, vaccines and biologicals:
neonatal tetanus. https://www.who.int/immunization/monitoring_surveillance/
burden/vpd/surveillance_type/active/neonatal_tetanus/en/.
Yang, J., Lee, S.H., Goddard, M.E., and Visscher, P.M. (2011a). GCTA: a
tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88,
76–82.
Yang, J., Weedon, M.N., Purcell, S., Lettre, G., Estrada, K., Willer, C.J., Smith,
A.V., Ingelsson, E., O’Connell, J.R., Mangino, M., et al.; GIANT Consortium
(2011b). Genomic inflation factors under polygenic inheritance. Eur. J. Hum.
Genet. 19, 807–812.
Yang, J., Lee, T., Kim, J., Cho, M.C., Han, B.G., Lee, J.Y., Lee, H.J., Cho, S.,
and Kim, H. (2013). Ubiquitous polygenicity of human complex traits: genome-
wide analysis of 49 traits in Koreans. PLoS Genet. 9, e1003355.
Zeller, T., Wild, P., Szymczak, S., Rotival, M., Schillert, A., Castagne, R.,
Maouche, S., Germain, M., Lackner, K., Rossmann, H., et al. (2010). Genetics
and beyond—the transcriptome of human monocytes and disease suscepti-
bility. PLoS ONE 5, e10693.
Cell Reports 27, 3241–3253, June 11, 2019 3253
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
1000 Genomes variant reference set http://www.internationalgenome.org/
data#download
1000 Genomes Phase I integrated variant set
release (March 2012) as the variant reference set
Type 1 Diabetes Genetics Consortium
reference panel
Wellcome Centre for Human genetics Consortium reference panel (5225 unrelated
individuals)
Critical Commercial Assays
Illumina OmniExpress12v1 Illumina, California, United States Cat#WG-311-1125
Illumina OmniExpress12v1.1 Illumina, California, United States Cat#WG-312-1120
Illumina scanner with
lluminaBeadStudio software
Illumina, California, United States Cat#SY-101-1001
Oligonucleotides
Custom TaqMan SNP Genotyping
Assays rs2523650
https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/real-time-pcr-assays/
snp-genotyping-taqman-assays.html
Cat#4331349
Custom TaqMan SNP Genotyping
Assays rs6903608
https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/real-time-pcr-assays/
snp-genotyping-taqman-assays.html
Cat#4331349
Custom TaqMan SNP Genotyping
Assays rs3094188
https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/real-time-pcr-assays/
snp-genotyping-taqman-assays.html
Cat#4331349
Custom TaqMan SNP Genotyping
Assays rs9268877
https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/real-time-pcr-assays/
snp-genotyping-taqman-assays.html
Cat#4331349
Custom TaqMan SNP Genotyping
Assays rs2523663
https://www.thermofisher.com/us/en/home/life-
science/pcr/real-time-pcr/real-time-pcr-assays/
snp-genotyping-taqman-assays.html
Cat#4331349
Software and Algorithms
PLINK whole genome association
analysis toolset
http://zzz.bwh.harvard.edu/plink/ PLINK version 1.9
SMARTPCA software https://www.hsph.harvard.edu/alkes-price/
software/
EIGENSOFT version 4.2
Segmented HAPlotype Estimation
and Imputation Tool
Delaneau et al., 2013 SHAPEIT version 2
IMPUTE Howie et al., 2009 IMPUTE version 2
SNP2HLA http://software.broadinstitute.org/mpg/snp2hla/ SNP2HLA version 1.0.1
NetMHCIIpan http://www.cbs.dtu.dk/services/NetMHCIIpan/ NetMHCIIpan version 3.1
SNPTEST https://mathgen.stats.ox.ac.uk/genetics_
software/snptest/snptest.html
SNPTEST version 2.4.0
Genome-wide SNPs for complex
traits (the GREML method)
https://cnsgenomics.com/software/
gcta/#Overview
GCTA version 1.91.7 (beta)
Deposited Data
Raw genotyping data, meta-data
and analysis script
https://data.mendeley.com O’Connor, Daniel (2019), ‘‘Common genetic
variations associated with the persistence of
immunity following childhood immunisation,’’
Mendeley Data, V1 (https://doi.org/null/
d7y6jhc36b.1)
R code algorithm devised to select
SNPs for stage 2
https://github.com https://github.com/dan-scholar/LD_pruning
e1 Cell Reports 27, 3241–3253.e1–e4, June 11, 2019
CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and data should be directed to and will be fulfilled by the Lead Contact, Daniel
O’Connor (daniel.oconnor@pediatrics.ox.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Study participants and vaccines
Healthy children and adolescents were included from nine studies conducted in Oxford, United Kingdom and one study conducted in
Bilthoven, Netherlands (1634 males and 1795 females; demographics are shown in Table S1). In accordance with national guidelines
(UK and Netherlands) immunisations were not delayed for minor illnesses but were deferred during acute illness (with fever
above 38C) until recovery. Regional research ethics committees approved these studies and the genetic analysis presented in
this work (CO2.328, 07/Q1605/34, 09/H0604/107, 10/H0604/07, 04/Q1604/28, 06/Q1604/67, Stichting Therapeutische Evaluatie
Geneesmiddelen [R05-044], B07/Q1605/41,10/H0504/25).
In brief, cohorts 1 and 2 were studies to examine the persistence serological of immunity to MenC in adolescents aged 11-20
years; 3-5 years after immunisation with a single dose of MenC vaccine, as part of the UK MenC catch-up immunisation pro-
gram (Snape et al., 2006, 2008a). Participants received one of three vaccines administered during the UK MenC vaccine
campaign: two of which contained MenC capsular polysaccharide conjugated to CRM197 and the other was conjugated to
TT. These vaccines were Menjugate (Novartis Vaccines and Diagnostics, Siena), Meningitec (Wyeth Vaccines, New York),
and NeisVac-C (Baxter Vaccines, Maryland). While Hib vaccination status was recorded for these participants, the vaccine for-
mation was not noted.
Cohort 3 was a group of infants from a study assessing the immunogenicity of the Hib-MenC conjugate vaccine (Pace et al., 2007).
Study participants received 3-doses of Hib-MenC (Menitorix, GSK Biologicals), which is conjugated to TT, or Meningitec, at 2, 3, and
4 months of age. Persistence of immunity to MenC, Hib and TT was assessed at 1 year of age. Cohorts 5 and 7 were infants enrolled
into studies evaluating the immunogenicity of immunisation with 2- or 3-doses of capsular group A, C, W and Y quadrivalent menin-
gococcal CRM-conjugated vaccine Menveo (Novartis Vaccines and Diagnostics, Siena) at 2, 3, 4 months or 2 and 4 months of age
(Blanchard-Rohner et al., 2013; Snape et al., 2008b). Participants also received their routine infant immunisation, in accordance with
the UK schedule, of relevance Pediacel (DTaP-Hib-IPV, Sanofi-Pasteur-MSD, Maidenhead, United Kingdom) was administered at 2,
3, 4 months of age; persistence of MenC and Hib immunity was measured at 1 year of age. Cohort 4 comprised of infants recruited
into a study evaluating immunological memory following infant MenC conjugate vaccine (Menjugate or NeisVac-C) in consistent or
alternating limbs. Participants received either a single dose of Menjugate or NeisVac-C at 3 months of age or a 2-dose schedule of
Menjugate at 3 and 4 months of age; administered concomitantly with routine immunisations including Pediacel at 2, 3, 4 months of
age (Khatami et al., 2014). Persistence of immunity to MenC and Hib was measured at 1 year of age.
Cohort 6 entailed a study evaluating the immunogenicity of the 2009 pandemic H1N1 influenza vaccine, in children 6 months to 12
years of age; data were also collected on routine childhood immunisations and sera were assessed to determine immunity to MenC,
Hib and TT vaccines (Waddington et al., 2010). Cohort 8 was a study assessing the immunogenicity of the 7- and 13-valent pneu-
mococcal conjugate vaccine alongside routine infant immunisations. As part of this study participants received NeisVac-C at
2 and 4 months of age and Pediacel at 2, 3, and 4 months of age. Persistence of vaccine-induced immunity was measured at
1 year of age (Snape et al., 2010). Cohort 9 was a longitudinal study assessing kinetics of the decline in MenC-specific antibody
following early childhood (1-4 years of age) MenC immunisation, as part of the UK MenC catch-up immunisation program (Khatami
et al., 2011). All of these children received a single dose of a licensed MenC conjugate vaccine of Menjugate, Meningitec or
NeisVac-C. Cohort 10 examined the persistence of serological immunity to MenC in adolescents aged 9-20 years; 3-5 years after
immunisation with a single dose of NeisVac-C, as part of the Dutch national MenC catch-up immunisation program (de Voer
et al., 2010). These participants received their last dose of Hib containing vaccine (Pediacel) at 11 months of age; and their last
dose of TT containing vaccine (assuming only routine immunisation) at 9 years of age or as a carrier protein to the MenC vaccine
in year 2002.
METHOD DETAILS
Serum bactericidal assays
The Vaccine Evaluation Unit (VEU), Public Health England (Manchester), performedMenC-specific SBAs for study cohorts 2, 8 and 9
using rabbit complement (rSBA), and using human complement (hSBA) for cohorts 4 and 6. Novartis Vaccines, Germany (Marburg),
performedMenC-specific SBAs using human complement for cohorts 1, 5 and 7 (Snape et al., 2006). GSK Biologicals, Belgium, per-
formed MenC-specific hSBA titers using human complement for cohort 3 (Pace et al., 2007). Rijksinstituut voor Volksgezondheid en
Milieu (RIVM), Bilthoven, measured MenC-specific rSBA titers using rabbit complement for cohort 10 (Maslanka et al., 1997). The
lower limit of quantification (LLQ) for the hSBA assays was a reciprocal titer of 4 and for the rSBA assay this was 8, sera without
detectable bactericidal antibody were assigned an arbitrary value of two.
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MenC-specific IgG concentrations
Novartis Vaccines, Germany (Marburg), performed MenC-specific IgG for Cohort 1, by a standardized enzyme-linked immunosor-
bent assay (ELISA) with a LLQ of 0.3 mg/ml (Snape et al., 2006). MenC-specific IgG concentrations weremeasured by ELISA in-house
for cohorts 2 and 7, with a LLQ of 0.00167 mg/mL (Blanchard-Rohner et al., 2013). MenC-specific IgG concentrations weremeasured
using ELISA at GlaxoSmithKline Biologicals, Belgium, for Cohort 3, with a LLQ of 0.3 mg/mL (32). MenC-specific IgG concentrations
were measured at the Vaccine Evaluation Unit (VEU), Public Health England (Manchester) by ELISA for Cohort 4 and 6, with a LLQ of
0.12 mg/mL (Gheesling et al., 1994). MenC-specific IgG concentrations were measured at the RIVM, Bilthoven, by multiplexed
immune assay (Bioplex) for Cohort 10, with a LLQ of 0.01 mg/mL (de Voer et al., 2009). For the purposes of analysis MenC-specific
IgG concentrations below the LLQ were assigned of half the respective assay LLQ.
Hib-specific IgG concentrations
An in-house ELISA was performed to measure Hib-specific IgG concentrations for cohort 2, with a LLQ of 100ng/ml (Booy et al.,
1992). Hib-specific IgG concentrations were measured at Public Health England (Manchester), by Bioplex PHE for Cohort
4 and 6, with a LLQ of 46 ng/ml (Pickering et al., 2002). GlaxoSmithKline Biologicals, Belgium, performed Hib-specific IgG
quantification for Cohort 3, by ELISA with a LLQ of 150ng/ml (Pace et al., 2007). Hib-specific IgG concentrations for Cohort 10
were assessed at RIVM, Bilthoven, by multiplexed immune assay, with a LLQ of 0.01 mg /ml (Pickering et al., 2002).
TT-specific IgG concentrations
TT-specific IgG concentrations were measured using ELISA at GlaxoSmithKline Biologicals, Belgium, for Cohort 3, the LLQ for this
assaywas 0.1IU/ml (Pace et al., 2007). Vaccine Evaluation Unit (VEU), Public Health England (Manchester) performed TT-specific IgG
quantification using Bioplex PHE for Cohort 4 and 6, with a LLQ of 2 (IU3 1000/ml) (Pickering et al., 2002). Aventis Pasteur, Toronto,
measured TT-specific IgGCohort 9, using an ELISAwith an in-house reference standard, the LLQ for this assaywas 0.1 IU/ml (Collins
et al., 2004). TT-specific IgG concentrations were measured using ELISA at Novartis Vaccines, Germany (Marburg) for Cohort 5, with
a LLQ of 0.1 IU/ml (Snape et al., 2008b). RIVM, Bilthoven, measured TT-specific IgG concentrations usingmultiplexed immune assay,
for Cohort 10, with a LLQ of 0.001 IU/ml (Pickering et al., 2002).
DNA extraction and genotyping
DNA was extracted either extracted from whole blood collected in EDTA tubes or from clotted whole blood samples. In the case of
clotted samples, 1ml of blood clots (remaining from serum separated peripheral blood) were placed in a Clotspin basket (QIAGEN,
Hilden, Germany) and centrifuged at 2000 3 g0 for 5 minutes to disperse the clot. Then, 5 mL of red blood cell lysis solution
(16.52 g NH4Cl, 2 g KHCO3 and 0.074 g DNA in 2l of H2O) was added, samples were vortexed for 3 s, and shaken for 5 minutes
on an orbital mixer at 120-200 rpm. Samples were vortexed for 3 s and centrifuged at 20003 g0 for 5 minutes. Supernatant was dis-
carded and an additional 5 mL of red blood cell lysis solution was added, vortexed for 3 s, before repeating the orbital mixer step.
Samples were centrifuged at 2000 3 g0, supernatant discarded and vortexed. Next, 1 mL of Cell Lysis solution (1 mL nuclei lysis
solution [Promega, Wisconsin, United States]; 25 mL Proteinase K [QIAGEN, Hilden, Germany]; and 250 mL 0.5 M ethylenediamine-
tetraacetic acid). Following this incubation, DNA was extracted according to the standard spin protocol for whole blood, using the
Qiampmidi kit (QIAGEN, Hilden, Germany). For blood samples collected directed into EDTA blood tubes (anticoagulant), the pre-
extraction process was skipped and DNA was extracted according to the standard spin protocol for whole blood, using the Qiamp
midi kit (QIAGEN, Hilden, Germany).
Genotyping of the discovery cohort (n = 2,061) was performed using either Illumina OmniExpress12v1 or OmniExpress-12v1.1
genotyping microarrays (Illumina, California, United States), at the Genome Institute of Singapore as according to manufacturers
protocol. In brief, DNA samples were whole-genome amplified and enzymatically cleaved into 300-600bp fragments. Samples were
then purified using isopropyl precipitation and re-suspended in hybridization buffer. Samples were hybridized to the microarray and
an allele-specific enzymatic single-base extension step was performed, to add a biotin-labeled (guanine or cytosine) or dinitro-
phenol-labeled (adenine or thymine) base. Sequential rounds of staining were performed with green-fluorescent streptavidin and
biotin-labeled antibodies, and red-fluorescent anti-dinitrophenol antibodies and dinitrophenol-labeled antibodies. Following stain-
ing, the arrays were read on an Illumina scanner and genotypes were called using Illumina BeadStudio software.
A number of quality control (QC) checks were undertaken on the genotyping data before statistical association testing, the QC
pipeline utilized was similar to that described by Anderson et al., 2010, using the PLINK whole genome association analysis toolset
(http://zzz.bwh.harvard.edu/plink/) (Anderson et al., 2010; Purcell et al., 2007). Participants with discrepancies between the sexes
(n = 81) reported on participant information data and those deduced from the genotyping data were removed. Participants with
genotype heterozygosity greater than two standard deviations from the cohort mean heterozygosity rate (n = 28), or with a missing
genotyping proportion > 0.03 were removed (n = 16). First- and second-degree relatives were identified identity-by-descent (IBD)
analysis, and all but the best-performing participant (in terms of genotype call-rate) were removed (n = 212). SMARTPCA software
was used to identify ancestral outliers, and population outliers were removed (n = 132) using themetrics described by Anderson et al.,
2010 (Anderson et al., 2010; Price et al., 2006). SNPs with minor allele frequencies (MAF) of < 0.01 (n = 77991), genotype call rate <
0.95 (n = 1984) and/or Hardy-Weinberg equilibrium (HWE) p values < 1 3 105 (n = 16305) were eliminated.
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Imputation
The post quality filtered dataset from the GWAS array was used for genotype imputation, Segmented HAPlotype Estimation and
Imputation Tool (SHAPEIT) version 2 was used to pre-phase each chromosome of the genotype data individually (Delaneau et al.,
2013). Imputation was performed using IMPUTE version 2 on 5 Mb chunks of this pre-phased data, applying the 1000 Genomes
Phase I integrated variant set release (March 2012) as the variant reference set (Howie et al., 2009). Imputed data were filtered for
MAF > 0.02, HWE p values > 1 3 109 and information scores > 0.8.
Imputation of classical HLA alleles
The SNP2HLA framework was used to impute classical human leucocyte antigen alleles from the genotype data, using the Type 1
Diabetes Genetics Consortium reference panel (5225 unrelated individuals) (Jia et al., 2013; Wellcome Trust Case Control Con-
sortium, 2007). Classical HLA alleles were annotated as present or absent, and a linear regression analysis was conducted using
PLINK 1.9 (Purcell et al., 2007). Conditional analysis of the five replication HLA SNPs including HLA DRB1*0301, HLA
DQB1*0201, HLA DQB1*0602 or HLA DRB1*1501, as covariate in the linear regression model was undertaken.
In silico epitope mapping
Clostridium tetani tetanus toxin protein sequence was retrieved fromUniProt (https://www.uniprot.org/). Tetanus toxin 20-mer, over-
lapping 19 amino acids, peptides were assessed against a panel of HLA-DRB1 alleles, using NetMHCIIpan 3.1 (http://www.cbs.dtu.
dk/services/NetMHCIIpan/), pan-specific MHC class II prediction tool.
QUANTIFICATION AND STATISTICAL ANALYSIS
Association analysis
A linear regression model was used to assess the relationship between SNP allele dosage and the persistence (> 120 days post-
vaccination) of log10 vaccine-specific measures. Analysis was conducted using SNPTEST version 2.4.0: incorporating age at vacci-
nation, time since vaccination, study enrolled in, complement source (for SBA analysis) and the first three principal components (PCs)
as covariates (Marchini and Howie, 2010). Post-association QC was also conducted to check for inflation, lambda gc (lgc), of test-
statistics, using the ‘GenABEL’ R package, under the assumption that the vastmajority of the geneticmarkers assessedwould not be
associated with the phenotype (Aulchenko et al., 2007). Genomic inflation was observed for regression analysis of TT-specific IgG
concentration (lgc = 2.30); however, this was ameliorated by the inclusion of the first 10 PCs into the regression model.
Heritability analysis
The GREML method was used to estimate the phenotypic variance explained by all SNPs, as described by Yang et al., 2011a (Yang
et al., 2011a). Heritability analysis used only the genome-wide genotyping data generated from the discovery cohort.
Replication SNP selection
The R code for the algorithm devised to select SNPs for stage 2 is deposited onGithub (https://github.com/dan-scholar/LD_pruning).
In brief, genotyped SNPs from stage 1 with association p values < 13 104, as well as imputed SNPs with p values < 13 105, in the
regression models of MenC-specific IgG concentrations or SBA titers were selected. A different statistical cut-off for genotyped and
imputed SNPs was imposed as imputed SNPs have an inevitable reduced certainty. These SNPs were separated into 500kb chro-
mosomal windows and windows with < 3 SNPs were eliminated as these are more likely to represent genotyping and/or imputation
errors. Next, to avoid redundant genotyping of markers in high LD the SNP list was pruned by filtering SNPs with an R2 > 0.95 with the
lead SNP within each 500kb window. Then, the next most significant SNP remaining in each window was selected and LD filtering
repeated iteratively, until all SNPs had been interrogated. We carried out combined analysis of the individual level discovery- and
replication-stage data in a single analysis, for both additive and dominant genetic models, using PLINK 1.9 (Purcell et al., 2007).
Meta-analysis of the discovery- and replication-stage cohorts was conducted by the inverse variance method, without adjusting
for principal components, using PLINK 1.9 (Purcell et al., 2007).
Pleiotropic loci analysis
SNPs associated with the persistence of serological immunity toMenC, Hib or TT at a p < 13 104 were collapsed into genetic loci by
gene boundaries. Genes linked with more than one measure of vaccine immunity were interpreted as pleiotropic.
Transcription factor motif prediction
Sequences surrounding SNPs were evaluated for potential transcription factor (TF) binding sites and the allelic variants were consid-
ered for their impact on TF motifs, using the R package ‘motifbreakR’ (Coetzee et al., 2015).
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